Mecetronium

Mecetronium

SCHEMBL125030

CCCCCCCCCCCCCCCC[N+](C)(C)CC.CCOS(=O)(=O)[O-]

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 8/20 0.59
HTT P42858 2/20 0.59
KMT2A Q03164 1/20 0.59
HSP90AA1 P07900 2/20 0.57
RAD52 P43351 2/20 0.57
RECQL P46063 2/20 0.50
BBOX1 O75936 2/20 0.50
GLA P06280 1/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
EPHX2 P34913 1/20 0.50
BLM P54132 1/20 0.50
PLA2G1B P04054 1/20 0.40
ATG4B Q9Y4P1 1/20 0.40
LSS P48449 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6243130 1.00 DNM1 (0.59) DNM1HTTKMT2AHSP90AA1RAD52
SCHEMBL608118 1.00 DNM1 (0.59) DNM1HTTKMT2AHSP90AA1RAD52
SCHEMBL6900640 1.00 DNM1 (0.59) DNM1HTTKMT2AHSP90AA1RAD52
SCHEMBL1123347 1.00 DNM1 (0.59) DNM1HTTKMT2AHSP90AA1RAD52
SCHEMBL2904189 1.00 DNM1 (0.59) DNM1HTTKMT2AHSP90AA1RAD52
SCHEMBL12760650 1.00 DNM1 (0.59) DNM1HTTKMT2AHSP90AA1RAD52
Hydrochloric Acid SCHEMBL20496970 0.98 DNM1 (0.57) DNM1HTTKMT2AHSP90AA1RAD52
Mecetronium SCHEMBL11855665 0.97 DNM1 (0.55) DNM1HTTKMT2AHSP90AA1RAD52
SCHEMBL14742775 0.95 BBOX1 (0.55) DNM1HTTKMT2AHSP90AA1RAD52
SCHEMBL14743251 0.95 BBOX1 (0.55) DNM1HTTKMT2AHSP90AA1RAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661968-A1 DIHYDROTRIAZINE COMPOUND AND COMPOSITION FOR USE IN PODOLOGY, IN THE PROPHYLAXIS AND/OR TREATMENT OF FOOT DISORDERS, THE TREATMENT OF TATTOOS AND/OR TATTOO WOUNDS AND THE TREATMENT OF A PIERCING AND/OR PIERCING WOUNDS B. Braun Melsungen AG (DE) 2025-12-17 EP claimed
EP-4661674-A1 ANTIMICROBIAL MEDICAL PRODUCT B. Braun Melsungen AG (DE) 2025-12-17 EP claimed
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 US claimed
WO-2024165485-A1 DIHYDROTRIAZINE COMPOUND AND COMPOSITION FOR USE IN PODOLOGY, IN THE PROPHYLAXIS AND/OR TREATMENT OF FOOT DISORDERS, THE TREATMENT OF TATTOOS AND/OR TATTOO WOUNDS AND THE TREATMENT OF A PIERCING AND/OR PIERCING WOUNDS B. BRAUN MELSUNGEN AG (DE) 2024-08-15 WO claimed
WO-2024165496-A1 ANTIMICROBIAL MEDICAL PRODUCT B. BRAUN MELSUNGEN AG (DE) 2024-08-15 WO claimed
US-20240173512-A1 METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS STREETERVILLE CAPITAL, LLC 2024-05-30 US claimed
US-11890421-B2 Methods for potentiating antimicrobial agents BEYOND AIR LTD (IL) 2024-02-06 US claimed
US-20230413810-A1 SANITISING FORMULATION LUMENDO AG (CH) 2023-12-28 US claimed
EP-4195922-A1 SANITISING FORMULATION Lumendo AG (CH) 2023-06-21 EP claimed
US-20220408729-A1 COMPOSITIONS CONTAINING METALLIC COMPOUNDS FOR PROLONGED DISINFECTION OF SURFACES AND THEIR USES NANOMATERIALES QUIMICOS AVANZADOS, S.A. DE C.V. (MX) 2022-12-29 US claimed
EP-0657896-B1 Method of making bubble and foreign particle free electrically conductive polyurethanes XEROX CORP (US) 2003-03-26 EP claimed
EP-1080715-A2 Combination of active agents and compositions for foot-care containing it Bode Chemie GmbH & Co. (DE) 2001-03-07 EP claimed
EP-0556546-B1 Viricidal disinfecting composition BODE CHEMIE GMBH & CO (DE) 2000-10-18 EP claimed
US-5454980-A Method of making bubble and foreign particle free electrically conductive polyurethanes XEROX CORPORATION (US) 1995-10-03 US claimed
EP-0657896-A1 Method of making bubble and foreign particle free electrically conductive polyurethanes XEROX CORPORATION (US) 1995-06-14 EP claimed
US-5286566-A Crosslinked chain extended polyetherurethane copolymer and asymmetric ionic quaternary ammonium salt XEROX CORPORATION (US) 1994-02-15 US claimed
US-5259989-A Polyurethane obtained from polytetramethylene ether glycol, at least one diisocyanate, crosslinking agents, chain extenders; asymmetric tetraalkylammonium alkyl sulfate XEROX CORPORATION (US) 1993-11-09 US claimed
EP-0556546-A2 Viricidal disinfecting composition Bode Chemie GmbH & Co. (DE) 1993-08-25 EP claimed
EP-0555634-A2 Disinfection compositions Bode Chemie GmbH & Co. (DE) 1993-08-18 EP claimed
EP-0238994-B1 PROCESS FOR PREPARING HIGH PURITY DERMATAN-SULPHATE, AND PHARMACEUTICAL COMPOSITIONS WICH CONTAIN IT MEDIOLANUM FARMACEUTICI s.r.l. (IT) 1991-07-17 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230413810-A1 SANITISING FORMULATION LPO, WASHC5, GFER DNM1 1033/4885HTT 1680/4885KMT2A 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.